Latest News

Executive transition and business backdrop at Remitly Global Remitly Global (RELY) has drawn fresh attention after outlining a planned Chief Accounting Officer transition alongside recent gains in active customers and free cash flow margins, a mix that keeps investors focused on execution. See our latest analysis for Remitly Global. At a share price of US$15.32, Remitly’s 1 day share price return of 2.07% and 90 day share price return of 10.53%, alongside a 1 year total shareholder return...

GATX (GATX) has attracted attention after recent share price pressure, including an approximately 9% decline over the past month. This has prompted investors to reassess the railcar and engine leasing company’s fundamentals and valuation. See our latest analysis for GATX. While the recent 9% one month share price decline has weighed on sentiment, GATX’s 1 year total shareholder return of about 9% and 3 year total shareholder return close to 60% show that the longer term picture has been...

NovaGold Resources (TSX:NG) has drawn fresh attention after a sharp month decline of 38.5%, even as its past year total return of 166.4% and 3 year total return of 31.0% stand out. See our latest analysis for NovaGold Resources. The recent 30 day share price return decline of 38.5% and year to date share price return decline of 11.3% contrasts with a 1 year total shareholder return of 166.4%. This suggests that shorter term momentum has faded, even as longer term holders still sit on...

Wondering if Bristol-Myers Squibb at around US$59.73 is a bargain or a value trap? This article walks through the key signals that matter for you as a shareholder or potential investor. The stock is up 4.8% over the last week and 11.7% year to date. However, the 30-day return is a 4.2% decline and the one-year return sits at 2.9%, with a three-year return of a 1.7% decline and a five-year return of 14.4%. Recent attention on large pharmaceutical names, including Bristol-Myers Squibb, has...

Novartis (SWX:NOVN) agreed to acquire Excellergy, a biotech focused on anti IgE therapies for allergic diseases, including food allergies. The company reported positive final two year Phase III results for Fabhalta in IgA nephropathy, indicating slower kidney function decline in the study population. The FDA granted Fabhalta priority review for traditional approval in IgA nephropathy. For investors watching large pharma, Novartis sits at the intersection of immunology, allergy, and kidney...

Bank of China (SEHK:3988) has reported FY 2025 results with fourth quarter revenue of C¥146.5b and basic EPS of C¥0.19, alongside trailing twelve month revenue of C¥559.1b and EPS of C¥0.74. Over recent periods the bank has seen quarterly revenue move from C¥137.9b in Q4 2024 to C¥146.5b in Q4 2025, while basic EPS shifted from C¥0.21 to C¥0.19 over the same quarters. With a trailing net profit margin of 41% and earnings quality described as high, the latest numbers point to solid, if finely...

Fosun International (SEHK:656) has reported FY 2025 first half revenue of C¥87.3b with basic EPS of C¥0.08, setting the stage against a trailing twelve month picture that includes a loss per share of C¥2.88 on revenue of C¥173.4b. Over recent periods, the company has seen first half revenue move from C¥97.8b in FY 2024 with EPS of C¥0.09, through second half FY 2024 revenue of C¥94.3b and an EPS loss of C¥0.62, into the latest half year where profitability remains pressured and margins look...

Wondering if National Energy Services Reunited at around US$20.81 is still offering value after its strong run, or if most of the opportunity has already been priced in. The stock has seen a 31.8% gain year to date and a very strong 182.7% return over the last year, although the past week and month show 5.1% and 16.9% declines that may be catching the eye of investors watching for a better entry point or shifting risk sentiment. Recent coverage has focused on how the market is reassessing...

Tencent Holdings (SEHK:700) remains a focal point for investors, with the share price at HK$484 and year to date total return at around a 22% decline, inviting closer attention to its current valuation. See our latest analysis for Tencent Holdings. Recent share price returns show pressure building rather than easing, with a 7 day share price return decline of 5.84% and a 90 day share price return decline of 19.20%. The 3 year total shareholder return of 28.82% contrasts with the year to date...

Recent share performance and business profile Canadian Pacific Kansas City (TSX:CP) has drawn attention after a recent month return of about a 10% decline, which contrasts with a gain of roughly 6% over the past 3 months and a 6% year-to-date move. The railway operator runs a transcontinental freight network across Canada, the United States and Mexico, moving bulk commodities, merchandise freight and intermodal containers over roughly 20,000 miles and generating CA$15,078 million in...

Why Salesforce stock is drawing attention now Salesforce (CRM) is back on many investors’ screens after a choppy run, with the share price showing a 3.2% gain over the past day but negative returns over the month and past 3 months. See our latest analysis for Salesforce. That 3.2% 1 day share price return to US$185.03 comes after a weaker patch, with a 30.4% 3 month share price decline and a 30.6% 1 year total shareholder return decline suggesting momentum has been fading recently. If...

Jiangsu Zenergy Battery Technologies Group (SEHK:3677) has just posted its FY 2025 numbers, with first half revenue of C¥3.2b and basic EPS of C¥0.09, set against trailing twelve month revenue of C¥8.1b and EPS of C¥0.33 that sit on top of very large year over year earnings growth. Over the past few reporting halves, revenue has moved from C¥1.8b and basic EPS of C¥0.06 in 1H FY 2024 to C¥3.2b and C¥0.09 in 1H FY 2025. Trailing net income has climbed alongside a net profit margin that is now...

In March 2026, Sociedad Química y Minera de Chile S.A. reported that its Board had unanimously agreed to recommend a final dividend of 50% of 2025 net income, equivalent to US$1.03 per share, to be paid in Chilean pesos in May 2026 if approved at the April 23, 2026 shareholders’ meeting. This proposed uplift from the current 30% payout policy highlights a shift toward returning a larger share of earnings to investors, contingent on 2025 profitability. We’ll now examine how this proposed move...

Medtide (SEHK:3880) has just posted its FY 2025 first half numbers, with revenue of ¥253.8 million and basic EPS of ¥0.82, set against trailing twelve month revenue of ¥570.1 million and EPS of ¥1.63 that sit alongside a reported year over year earnings growth figure of 267.3%. Over recent periods the company has seen revenue move from ¥197.5 million and EPS of ¥0.40 in the first half of FY 2024 to ¥244.8 million and EPS of ¥0.07 in the second half of FY 2024 and then to the latest ¥253.8...

If you are wondering whether XPeng's share price reflects its real worth, or if the market is mispricing the story, this article walks you through what the numbers are actually saying. XPeng's stock last closed at US$16.72, with returns of an 11.4% decline over 7 days, 4.8% decline over 30 days, 18.2% decline year to date and 19.3% decline over 1 year, set against a 52.0% gain over 3 years and 53.6% decline over 5 years. These mixed returns sit against a backdrop of ongoing headlines about...

Telesat (TSAT) stock has drawn attention after recent trading, with a 1 day return of about negative 9% and a 7 day move around negative 17%, following a strong past year and past 3 months. See our latest analysis for Telesat. Despite the recent pullback, with a 1 day share price return of negative 9.15% and a 7 day share price return of negative 17.34%, Telesat still shows stronger momentum over longer periods. This includes a 1 year total shareholder return of 78.70% and a 3 year total...

In March 2026, BlackSky Technology Inc. announced a seven-figure Assured extension contract with an international customer, alongside a US$47.812697 million ESOP-related shelf registration filing and a presentation by CTO Patrick O’Neil at the SATELLITE 2026 conference in Washington, D.C. The contract centers on BlackSky’s Gen-3 constellation, offering 35-centimeter imagery and AI-enabled analytics through its dual-generation, tip-and-cue architecture, underscoring growing customer appetite...

Nokian Renkaat Oyj (HLSE:TYRES) shares are in focus after the March 25, 2026 AGM, where investors saw a €0.25 per share dividend confirmed alongside Board refreshment and new committee appointments. See our latest analysis for Nokian Renkaat Oyj. The AGM news comes after a weaker period for the shares, with a 30 day share price return showing a decline of 14.76% and a year to date share price return showing a decline of 5.75%. However, the 1 year total shareholder return of 50.47% still...

Micron Technology has started mass production of its HBM4 memory for Nvidia's Vera Rubin platform. The company reports that its entire HBM4 production capacity for calendar 2026 is already committed under binding contracts. Micron has entered into its first five year customer agreement, an unusual move in a sector that typically works on shorter contracts. Micron Technology, NasdaqGS:MU, is stepping deeper into the high bandwidth memory segment at a time when its share price sits around...

PayPal Holdings, Inc. recently added Alyssa Henry, former CEO of Block’s Square business, to its Board of Directors while long‑time director Gail J. McGovern chose not to stand for re‑election at the upcoming 2026 Annual Meeting, alongside product, client, and conference updates across its payments and security operations. The global expansion of its dollar‑backed stablecoin PYUSD to 70 markets and deeper integration with Bybit EU highlight PayPal’s push to embed itself more firmly at the...

Wondering if Kratos Defense & Security Solutions is still reasonably priced after a strong run, or if the recent pullback has changed the picture? This breakdown is aimed squarely at helping you frame that question. The stock closed at US$65.28, with returns of 122.8% over 1 year and 391.2% over 3 years, but the last 7 days and 30 days show declines of 15.8% and 24.3% respectively, with the year-to-date return at a 17.7% decline. Recent headlines have focused on Kratos as a defense and...

Nanobiotix reported first clinical data from the Johnson & Johnson sponsored Phase 2 CONVERGE trial of JNJ-1900 (NBTXR3) in stage 3 inoperable non small cell lung cancer. Results presented at a major conference showed initial signals of efficacy alongside an acceptable safety profile. The data mark the first readout from a pivotal trial of Nanobiotix’s lead asset in this lung cancer setting. For investors watching ENXTPA:NANO, this update lands after a period of strong share price...

The UK stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices both experiencing declines amid concerns over China's economic recovery and its impact on global trade. Despite these broader market uncertainties, penny stocks continue to capture investor interest due to their potential for significant growth at relatively low price points. While the term "penny stocks" may seem outdated, these smaller or newer companies can offer compelling opportunities for those...

We wouldn't blame Hewlett Packard Enterprise Company ( NYSE:HPE ) shareholders if they were a little worried about the...